We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
UK pharma group says country’s chemistry prowess makes it a good source of molecules
US biotech company’s stock worth nearly $500 at its peak in August 2021, currently trades at less than $87
Belfast-based CV6 Therapeutics announced MHRA approval for trials of novel therapy pill
Sector benefits from shifts in interest rate expectations after 50% fall
Company would have been better off following Roche’s route to market for anti-obesity treatment
Decision sets up another potentially landmark ruling on reproductive rights as the country prepares for 2024 election
US drugmaker is trying to chart its future without blockbuster Covid-19 products
Proposals include measures to encourage stockpiling and investment incentives for new factories in bloc
Anglo-Swedish pharma group agrees to buy Seattle-based biotech Icosavax
Paul Hudson needs to convince investors that pharma group’s new blockbuster drugs will be successful
Paul Hudson is meeting investors to explain multibillion-euro push to get drug candidates to market
Evobrutinib would have more than compensated for falling sales from German group’s existing medicines
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
Wuxi Biologics is likely to miss its original sales target for the year by about $400mn
Pharma group behind blockbuster drug wants to supersize its market impact
Members of the company’s founding family fight to uphold protections from $6bn opioid bankruptcy settlement in closely watched case
The Swiss pharma group needs to settle investor jitters with its latest acquisition
Swiss pharmaceutical group is under pressure to strengthen its pipeline of medicines
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Group plans to refocus on 30 core brands
Decision is setback for US drugmaker looking to increase sales after pandemic
Key drugs are due to lose exclusivity in the important US market in 2027
Innovative models can drive funding for research on neglected, less survivable diseases
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
UK Edition
